Table 2.
Overestimation and underestimation of HCV RNA by CAP/CTM and the prototype CAP/CTM v2/MMx1 and v2/MMx2 assays in comparison to CAMa
| GT (no. of samples) | Discrepancy | No. of discrepant samples |
||
|---|---|---|---|---|
| CAP/CTM | CAP/CTM v2/MMx1 | CAP/CTM v2/MMx2 | ||
| GT1 (108) | Moderate | 6 (3+/3−) | 3+ | 4 (3+/1−) |
| Severe | 0 | 0 | 3+ | |
| GT2 (8) | Moderate | 4− | 1+ | 0 |
| Severe | 0 | 0 | 1+ | |
| GT3 (24) | Moderate | 9 (1+/8−) | 1+ | 0 |
| Severe | 3− | 0 | 0 | |
| GT4 (87) | Moderate | 35− | 13 (6+/7−) | 8 (2+/6−) |
| Severe | 17− | 1− | 1+ | |
| GT5 (3) | Moderate | 2− | 0 | 1− |
| Severe | 0 | 0 | 0 | |
| GT6 (2) | Moderate | 1− | 0 | 0 |
| Severe | 0 | 0 | 0 | |
a
Discrepancies are classified as follows: moderate, titer value differences between ±0.5 log10 and ±1.0 log10 IU/ml; severe, titer value differences >1.0 log10IU/ml; +, overquantification compared to the reference assay.